<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113694</url>
  </required_header>
  <id_info>
    <org_study_id>CEP298</org_study_id>
    <nct_id>NCT04113694</nct_id>
  </id_info>
  <brief_title>Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes</brief_title>
  <official_title>Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, non-randomized, prospective single arm study with Type 1
      patients with diabetes on insulin pump therapy with Continuous Glucose Monitoring (CGM).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects taking Novolog - Rate of infusion set failure at the end of Day 6</measure>
    <time_frame>144 hours</time_frame>
    <description>Rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects taking Humalog - Rate of infusion set failure at the end of Day 6</measure>
    <time_frame>144 hours</time_frame>
    <description>Independently evaluate rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects taking Novolog - Rate of infusion set failure at the end of Day 7.</measure>
    <time_frame>168 hours</time_frame>
    <description>Rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects taking Humalog - Rate of infusion set failure at the end of Day 7.</measure>
    <time_frame>168 hours</time_frame>
    <description>Independently evaluate rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Extended Wear Infusion Set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be given 12 Extended Wear Infusion Sets to wear.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extended Infusion Set</intervention_name>
    <description>Subjects will perform each Extended Wear Infusion Set wear for at least 174 hours.</description>
    <arm_group_label>Extended Wear Infusion Set</arm_group_label>
    <other_name>Extended Wear Infusion Set</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is age 18 - 80 years at the time of screening

          2. Subject has type 1 diabetes for more than one year Study specific inclusion criteria

          3. Subject is on the MiniMed™ 670G insulin pump therapy within 1 year prior to screening
             and willing to utilize Auto Mode and CGM with Guardian™ Sensor (3) during the study.

          4. Subject is willing and able to perform study procedures as per investigator discretion

          5. Subject is willing to take one of the following insulins and can financially support
             the use of either of the 2 insulin preparations throughout the course of the study
             (i.e. co-payments for insulin with insurance or able to pay full amount):

               1. Humalog™* (insulin lispro injection)

               2. NovoLog™* (insulin aspart)

        Exclusion Criteria:

          1. Subject is actively participating in an investigational study (drug or device) wherein
             he/she has received treatment from an investigational study drug or investigational
             study device in the last 2 weeks.

          2. Subject is female and has a positive pregnancy screening test

          3. Subject is female of child bearing age and who is sexually active should be excluded
             if she is not using a form of contraception deemed reliable by investigator

          4. Subject is female and plans to become pregnant during the course of the study

          5. Subject has Glycosylated hemoglobin (HbA1c) &gt; 8.5 % at time of screening. Note: All
             HbA1c blood specimens will be sent to and tested by a NGSP certified Central
             Laboratory. HbA1c testing must follow National Glycohemoglobin Standardization Program
             (NGSP) standards.

          6. Subject has had a history of 1 or more episodes of severe hypoglycemia, which resulted
             in any the following during the 6 months prior to screening

               1. Medical assistance (i.e. Paramedics, Emergency Room [ER] or Hospitalization)

               2. Coma

               3. Seizures

          7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time
             of screening visit, or plans to take any oral, injectable, or IV glucocorticoids
             during the course of the study.

          8. Subject is unable to tolerate tape adhesive in the area of infusion set

          9. Subject has any unresolved adverse skin condition in the area of infusion set
             placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

         10. Subject has infection in the area of infusion set placement at time of screening

         11. Subject has had Diabetic Ketoacidosis (DKA) in the 12 months prior to screening visit.

         12. Subject is currently abusing illicit drugs

         13. Subject is currently abusing alcohol

         14. Subject is on dialysis (for renal failure)

         15. Subject has history of adrenal disorder

         16. Subject has a history of inpatient psychiatric treatment in the past 6 months prior to
             screening

         17. Subject has any condition that the Investigator believes would interfere with study
             participation

         18. Subject has a history of visual impairment which would not allow subject to
             participate in the study and perform all study procedures safely, as determined by the
             investigator

         19. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell
             transfusion or erythropoietin within 3 months prior to time of screening

         20. Subject plans to receive red blood cell transfusion or erythropoietin over the course
             of study participation

         21. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides,
             DPP-4 inhibitors or sulfonylureas more than 2 weeks from time of screening

         22. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting
             in chronic anemia

         23. Subject has history of cardiovascular disease defined as any ischemic related event or
             clinically significant arrythmia.

         24. Subject has hypothyroidism and has out of reference range thyroid-stimulating hormone
             (TSH) on screening visit (prior labs in the last 3 months are sufficient). Subject may
             repeat TSH draw to verify eligibility if not in range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Investigations</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grunberger Diabetes Institute</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Rochester MN)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrinology Consultants of Pennsylvania</name>
      <address>
        <city>Feasterville-Trevose</city>
        <state>Pennsylvania</state>
        <zip>19053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

